Prevention & Risk Modification

Videos

Supplement

Postpartum Cardiomyopathy and Considerations for Breastfeeding

Postpartum cardiomyopathy (PPCM) is a diagnosis of exclusion, where patients present with heart failure secondary to left ventricular (LV) systolic dysfunction towards the end of pregnancy or in the months following delivery, with no other cause of heart failure identified.1 PPCM is relatively uncommon, affecting between one in 5,000 and one in 10,000 births;2 it is thought to be more prevalent in women aged over 30 years, of black ethnicity, with a history of pre-eclampsia or preg

Neuroendocrine System Regulatory Mechanisms: Acute Coronary Syndrome and Stress Hyperglycaemia

The aim of reviewing the neuroendocrine–humoral response in acute coronary syndrome (ACS) is based on the fact that beyond the distinctive thrombotic event that defines acute occlusion of a coronary artery, generically referred to as a plaque accident, it is not an isolated event.

ISCP Guest Editorial: Cardiovascular Disease Prevention in Diabetes

Type 2 diabetes is a major risk factor for the development of cardiovascular disease (CVD) such as MI, and cerebrovascular incidents such as stroke. A substantial body of evidence has indicated that the proper management of blood glucose in people with diabetes can inhibit the progression of microvascular disease such as retinopathy and nephropathy.

Familial Hypercholesterolaemia Diagnosis and Management

Familial hypercholesterolaemia (FH) is the genetic disorder most commonly associated with elevated LDL cholesterol (LDL-C) levels from birth and with premature atherosclerotic cardiovascular disease (ASCVD).1 It is caused by mutations in genes related to the clearance of LDLs such as LDL receptor (LDLR), apolipoprotein B-100 (APOB) and proprotein convertase subtilisin/kexin type 9 (PCSK9).

Management of Severe Dyslipidaemia: Role of PCSK9 Inhibitors

Therapeutic targeting of dyslipidaemia has been one of the major successes in cardiovascular medicine over the last three decades. On the basis of unequivocal evidence from animal models through to both population and genetic studies in humans, there is a clear association between increasing levels of LDL cholesterol (LDL-C) and incident cardiovascular risk.1 This has prompted efforts to develop a range of therapeutic strategies that lower LDL-C levels.